Pipeline

ADG126

ADG126

Our SAFEbody product candidate, ADG126 is a fully human anti-CTLA-4 SAFEbody designed to address the safety concerns associated with existing CTLA-4 therapeutics. It is designed to enhance the safety features by masking the antibody binding site of ADG126, which would be unmasked in the TME, where the activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of enhanced antibody-dependent cellular cytotoxicity, or ADCC.

A global phase 1 clinical trial is evaluating the safety and tolerability of ADG126 in patients with advanced/metastatic solid tumors, with dose escalation ongoing. Publications →